Eisai and Merck Announce FDA Grants Breakthrough Therapy Designation For LENVIMA In Combination With KEYTRUDA As Therapy For Previously Treated Patients With Advanced And/Or Metastatic Non-MSI-H/pMMR Endometrial Carcinoma